# US 2014/0155383 A1 · Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155383 A1
- Document ID: US20140155383A1
- Status: Published application
- Kind: A1
- Application number: 14/118,222
- Filed: 2012-05-11
- Published: 2014-06-05
- Earliest claimed: 2011-05-16
- Assignees: Bayer Intellectual Property GmbH
- Inventors: Stefan Golz; Martina Delbeck; Heinrich Meier; Andreas Geerts; Thomas Mondritzki; Hubert Trübel
- Web page: https://patentgrep.com/patent/US20140155383A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/415: 1,2-Diazoles
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.

## Claims

### Claim 1

A method of treatment and/or prophylaxis of pulmonary hypertension and/or acute or chronic heart failure comprising administering an effective amount of a Cathepsin K inhibitor to a human or animal in need thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Cathepsin K inhibitor is a compound of formula (I) to (XIV) or (XV)
Com-
Stucture
pound
Name
(I)
(II)
(III)
(IV)
(V)
(VI)
(VII)
(VIII)
(IX)
MIV 701 (X), Ono 5334 (XI), RO 4383315 (XII), SAR-114137 (XIII), MIV 710 (XIV) or MIV 711 (XV).

### Claim 3 (depends on 1)

The method of claim 1, wherein the Cathepsin K inhibitor is a compound of formula (I)

### Claim 4

A method of treatment and/or prophylaxis of pulmonary hypertension comprising administering to a human or animal in need thereof an effective amount of a compound of formula (I)
or a salt thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the Cathepsin K inhibitor is administered orally.

### Claim 6

A method for the treatment and/or prophylaxis of pulmonary hypertension and/or acute or chronic heart failure in humans and animals comprising administering to a human or animal a therpeutically effective amount of a pharmaceutical composition comprising at least one Cathepsin K inhibitor and an inert, non-toxic, pharmaceutically acceptable additive.

### Claim 7 (depends on 6)

The method of claim 6, wherein compound of formula (I) to (XIV) or (XV)
Com-
Stucture
pound
Name
(I)
(II)
(III)
(IV)
(V)
(VI)
(VII)
(VIII)
(IX)
MIV 701 (X), Ono 5334 (XI), RO 4383315 (XII), SAR-114137 (XIII), MIV 710 (XIV) or MIV 711 (XV).

### Claim 8 (depends on 6)

The method of claim 6, wherein the Cathepsin K inhibitor is a compound of formula (I)
for the use in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or acute or chronic heart failure and/or combinations thereof.